AVEO Oncology

AVEO Oncology is a global, oncology-focused biopharmaceutical company committed to delivering medicines that improve the lives of cancer patients. Their mission is to become a top 20 oncology leader within the next five years, leveraging a robust portfolio of innovative products and deep capabilities spanning discovery, clinical development, biologics manufacturing, and US commercialization. Their lead candidate, FOTIVDA® (tivozanib), is an oral, once-daily, differentiated vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) approved for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC).

In addition to FOTIVDA®, AVEO has a diverse pipeline of product candidates, including ficlatuzumab (anti-HGF IgG1 mAb), AV-380 (anti-GDF15 IgG1 mAb), AV-203 (anti-ErbB3 mAb), and AV-353 (anti-Notch 3 mAb). They are dedicated to building strong partnerships with other companies in the oncology space, to accelerate their development efforts and deliver innovative treatments to patients. AVEO Oncology was acquired by LG Chem in January 2023, expanding LG Chem's Life Sciences' oncology portfolio.

AVEO Oncology recognizes the changing needs of its employees and strives to provide flexibility in the workplace. While the company's website does not provide specific details about its remote work policy or other flexible work arrangements, it highlights the company's commitment to providing a "People First" culture where employees feel valued and supported. This commitment is reflected in their recognition as a Top Place to Work in Massachusetts for two consecutive years, suggesting that AVEO Oncology offers a workplace that prioritizes the needs of its employees and promotes a positive work-life balance.

AVEO Oncology, an LG Chem company, is a biopharmaceutical company dedicated to developing and commercializing innovative therapies to improve the lives of patients with cancer. Their mission is to passionately pursue a better life for patients with cancer by delivering medicines that provide effective treatments while allowing patients to maintain their quality of life. AVEO focuses on developing and commercializing therapies that target specific pathways involved in cancer growth and spread, with a particular emphasis on renal cell carcinoma (RCC). They are committed to fostering a culture of collaboration, innovation, and patient-centricity to achieve their goals.

AVEO Oncology promotes a culture that is patient-focused, science-driven, and collaborative. They believe in providing employees with opportunities for professional development through diverse exposure, open communication, and a positive work environment. They also value community service, with employees participating in activities like assembling emergency kits for hurricane victims and fundraising for cancer research. This dedication to both professional and community engagement creates a vibrant, unified, and purpose-driven corporate culture that fosters respect, urgency, integrity, and goal orientation.

AVEO Oncology is committed to creating a diverse, equitable, and inclusive work environment. They recognize the strength and value that diversity brings to the workplace and strive to create an environment where everyone feels valued and respected. AVEO is committed to providing equal opportunities for all qualified applicants and employees regardless of their race, color, religion, sex, sexual orientation, gender identity, national origin, disability, or status as a protected veteran.